Giammaria Fiorentini, MD, Donatella Sarti, PhD, Camillo Aliberti, MD, Riccardo Carandina, MD, Luca Mulazzani, MD, Alessandro Felicioli, MD, Stefano Guadagni, MD
Featured product:
19/12/2018 -
Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.
Source: https://www.jvir.org/article/S1051-0443(18)31125-4/abstract
This is HCP only content
This site uses cookies. Functional cookies are necessary for the use of this website and cannot be refused. Other cookies are only placed if you choose to do so. For further information please read our cookies notice.
This site uses cookies. Functional cookies are necessary for the use of this ... website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.